ArticleCancer2026

Longitudinal analysis of tyrosine kinase inhibitor therapy outcomes and BCR-ABL1 transcript decline velocity in chronic myeloid leukemia: A 16-year real-world study.

Moaath K Mustafa Ali et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.